جارٍ التحقق…
تُرجمت تلقائيًا. للجرعات والتحذيرات: راجع النص الأصلي بالإنجليزية. اقرأ بالإنجليزية
الرئيسية / Registered in Nigeria / Tecentriq 840 mg/14 mL

Tecentriq 840 mg/14 mL

NAFDAC Reg. No. A6-100033 · Drug

Registered with NAFDAC. Registration activeAs of 17 November 2026 · synced automatically from official sources.
Product
Tecentriq 840 mg/14 mL
رقم NAFDAC
A6-100033
المادة الفعالة
Atezolizumab
التركيز
840 mg/14 mL
الشكل
Concentrate for solution for infusion
حجم العبوة
1 x 1's (in vial)
Manufacturer
Not listed
Applicant (holder)
Roche Products Limited
Approved
28 Oct 2021
الحالة
Inactive View on NAFDAC ↗
التسجيل ساري حتى
27 Oct 2026
تنبيهات منظمة الصحة العالمية
None found
Community reports
None
Times checked
0

About the medicine: Atezolizumab: uses, dosage and brands worldwide

What we found

  • Tecentriq 840 mg/14 mL is on the NAFDAC register with an active registration (A6-100033). A valid number alone does not prove a pack is genuine — counterfeiters copy real numbers, so also check the expiry date, seal and print quality.

Generated automatically from the NAFDAC register, WHO alerts and community data as of today. This is not medical advice. Always follow your doctor or pharmacist.

How to use Tecentriq 840 mg/14 mL

ما تقوله النشرة الرسمية. إذا وصفه لك طبيب، فاتبع الوصفة. وإذا اختلفت نشرة عبوتك، فالأولوية لها.

لمن هو

TECENTRIQ is a programmed death-ligand 1 (PD-L1) blocking antibody indicated: Non-Small Cell Lung Cancer (NSCLC) as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage II to IIIA NSCLC whose tumors have PD-L1 expression on ≥ 1% of tumor cells, as determined by an FDA-authorized test. ( 1.1 , 14.1 ) for the first-line treatment of adult patients with metastatic NSCLC whose tumors have high PD-L1 expression (PD-L1 stained ≥ 50% of tumor cells [TC ≥ 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 10% of the tumor area [IC ≥ 10%] ), as determined by an FDA-authorized test, with no EGFR or ALK genomic tumor aberrations. …

كيف يُتناول وكم مرة
  • Administer TECENTRIQ intravenously over 60 minutes
  • If the first infusion is tolerated, all subsequent infusions may be delivered over 30 minutes
  • NSCLC In the adjuvant setting, administer TECENTRIQ following resection and up to 4 cycles of platinum-based chemotherapy as 840 mg every 2 weeks, 1200 mg every 3 weeks or 1680 mg every 4 weeks for up to 1 year
  • In the metastatic setting, administer TECENTRIQ as 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks
  • When administering with chemotherapy with or without bevacizumab, administer TECENTRIQ prior to chemotherapy and bevacizumab when given on the same day
  • Small Cell Lung Cancer Administer TECENTRIQ as 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks
  • Administer TECENTRIQ prior to chemotherapy when given on the same day
  • Hepatocellular Carcinoma Administer TECENTRIQ as 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks
  • Administer TECENTRIQ prior to bevacizumab when given on the same day
  • Bevacizumab is administered at 15 mg/kg every 3 weeks
  • Melanoma Following completion of a 28-day cycle of cobimetinib and vemurafenib, administer TECENTRIQ 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks with cobimetinib 60 mg orally once daily (21 days on /7 days off) and vemurafenib 720 mg orally twice daily
  • ASPS
  • Adults: Administer TECENTRIQ as 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks. …
Strengths it comes in

Injection: 840 mg/14 mL (60 mg/mL) and 1200 mg/20 mL (60 mg/mL) colorless to slightly yellow solution in a single-dose vial. Injection: 840 mg/14 mL (60 mg/mL) and 1200 mg/20 mL (60 mg/mL) solution in a single-dose vial. ( 3 )

Children
  • Alveolar Soft Part Sarcoma The safety and effectiveness of TECENTRIQ for unresectable or metastatic ASPS have been established
  • In pediatric patients aged 2 years and older. Use of TECENTRIQ for this indication is supported by evidence from an adequate and well controlled study of TECENTRIQ
  • In adults and 2 adolescent
  • Pediatric patients (≥12 years of age) with ASPS with additional pharmacokinetic and safety data in pediatric patients 2 years to
Older adults

TECENTRIQ as a Single-Agent Of 2616 patients with metastatic NSCLC and other tumor types treated with single agent TECENTRIQ in clinical studies, 49% were 65 years and over and 15% were 75 years and over. Of the 167 patients with MIBC treated with TECENTRIQ in IMvigor011, 117 (70%) patients were 65 years of age and older and 44 (26%) patients were 75 years of age and older. …

While you are taking it
  • Advise the patient to read the FDA-approved patient labeling (Medication Guide)
  • Immune-Mediated Adverse Reactions Inform patients of the risk of immune-mediated adverse reactions that may require corticosteroid treatment and interruption or discontinuation of TECENTRIQ, including: Pneumonitis : Advise patients to contact their healthcare provider immediately for any new or worsening cough, chest pain, or shortness of breath [see Warnings and Precautions ]
  • Colitis : Advise patients to contact their healthcare provider immediately for diarrhea, blood or mucus in stools, or severe abdominal pain [see Warnings and Precautions ] . …
Talk to a doctor first if
  • None
  • None
Warnings

Immune-Mediated Adverse Reactions Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue, including the following: immune-mediated pneumonitis, immune-mediated colitis, immune-mediated hepatitis, immune-mediated endocrinopathies, immune-mediated dermatologic adverse reactions, immune-mediated nephritis and renal dysfunction, and solid organ transplant rejection. ( 5.1 ) Monitor for early identification and management. Evaluate liver enzymes, creatinine, and thyroid function at baseline and periodically during treatment. ( 5.1 ) Withhold or permanently discontinue based on severity and type of reaction. …

الآثار الجانبية المحتملة

The following clinically significant adverse reactions are described elsewhere in the labeling: Severe and Fatal Immune-Mediated Adverse Reactions [see Warnings and Precautions (5.1) ] Infusion-Related Reactions [see Warnings and Precautions (5.2) ] Complications of Allogeneic HSCT after PD-1/PD-L1 Inhibitors [see Warnings and Precautions (5.3) ] TECENTRIQ as a single-agent Most common adverse reactions (≥ 20%) with TECENTRIQ as a single-agent are fatigue/asthenia, decreased appetite, nausea, cough, and dyspnea. …

Pregnancy and breastfeeding

8.1 Pregnancy Risk Summary Based on its mechanism of action [see Clinical Pharmacology (12.1) ] , TECENTRIQ can cause fetal harm when administered to a pregnant woman. There are no available data on the use of TECENTRIQ in pregnant women. Animal studies have demonstrated that inhibition of the PD-L1/PD-1 pathway can lead to increased risk of immune-related rejection of the developing fetus resulting in fetal death (see Data ) . …

How to store it

Store vials under refrigeration at 2°C to 8°C (36°F to 46°F) in original carton to protect from light. Do not freeze. Do not shake.

إذا نسيت جرعة

تناولها عندما تتذكر، إلا إذا اقترب موعد الجرعة التالية. عندها تخطَّ الجرعة المنسية. لا تتناول جرعتين معًا أبدًا للتعويض. راجع النشرة، فبعض الأدوية مختلفة.

From the official U.S. FDA label for this active ingredient. Your pack may have a different strength, so always read its leaflet. If a doctor prescribed it, follow the prescription. Ask a pharmacist if you are unsure. Label dated 2026-10-13.

Label for atezolizumab, the active ingredient registered with NAFDAC.

Check your pack of Tecentriq 840 mg/14 mL

Add the expiry date on your pack for a full Trust Score.

أو التقط صورًا للعبوة
تبقّت 3 عمليات تحقق مجانية اليوم Official sources: U.S. FDA · EMA (EU) · Health Canada · WHO alerts

About Tecentriq 840 mg/14 mL

What is in Tecentriq 840 mg/14 mL?

Tecentriq 840 mg/14 mL contains Atezolizumab (840 mg/14 mL), as concentrate for solution for infusion, according to its NAFDAC registration record.

Is Tecentriq 840 mg/14 mL registered with NAFDAC?

Yes. Tecentriq 840 mg/14 mL is listed on the NAFDAC register under registration number A6-100033, and its registration is active as of 17 November 2026.

Has Tecentriq 840 mg/14 mL been flagged as fake or recalled?

No WHO falsified or substandard medical product alert currently matches Tecentriq 840 mg/14 mL in our automatically synced alert list.

How can I check that my pack of Tecentriq 840 mg/14 mL is genuine?

Run a free authenticity scan with the NAFDAC number A6-100033, your pack's expiry date and batch number to get a Trust Score, compare the pack with the NAFDAC record (ingredient, strength, form, manufacturer), and buy only from licensed pharmacies.

How do I take Tecentriq 840 mg/14 mL?

Follow your prescription or the leaflet in your pack. The official label says: Administer TECENTRIQ intravenously over 60 minutes. If the first infusion is tolerated, all subsequent infusions may be delivered over 30 minutes. NSCLC In the adjuvant setting, administer TECENTRIQ following resection and up to 4 cycles of platinum-based chemotherapy as 840 mg every 2 weeks, 1200 mg every 3 weeks or 1680 mg every 4 weeks for up to 1 year. ( 2.2 ) In the metast…

What is Tecentriq 840 mg/14 mL used for?

TECENTRIQ is a programmed death-ligand 1 (PD-L1) blocking antibody indicated: Non-Small Cell Lung Cancer (NSCLC) as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage II to IIIA NSCLC whose tumors have PD-L1 expression on ≥ 1% of tumor cells, as determined by an FDA-authorized test. ( 1.1 , 14.1 ) for the first-line treatment of adult patients with (Summarised from the official U.S. FDA label for atezolizumab. Always follow your doctor or pharmacist.)

Patient reviews

–No reviews yet
5★
0
4★
0
3★
0
2★
0
1★
0
Have you used Tecentriq 840 mg/14 mL? Share your experience to help other patients. Sign in to review

Reviews are personal experiences from PillVera users, not medical advice. Report side effects to your doctor and to NAFDAC.